CASL webinars and other enduring educational resources can now be found in the HepatoSite, our online learning portal.
CASL members can access HepatoSite via the link in the ‘Members Only‘ area of the website.
Non-members may purchase access to select content – click here to create an account and browse the catalogue of resources.
Health Canada Resources on Drug Safety:
- Summary Safety Review Information Page
- January 2021: Health Canada Marketed Health Products Directorate correspondence regarding Sofosbuvir-containing products: Assessing the Potential Risk of Severe Cutaneous Adverse Reactions (SCAR) [English] [French]
- December 2020: Health Canada Marketed Health Products Directorate correspondence regarding direct-acting antivirals (DAAs) containing a protease-inhibitor: risks of hepatic decompensation and hepatic failure [English] [French]
- August 2019: FDA News Release regarding the rare occurrence of serious liver injury in patients who use certain hepatitis c medicines
The CIHR Institute of Nutrition, Metabolism and Diabetes INMD Connections newsletters:
Primary Care Treatment and Referral Pathways:
- Alberta NAFLD Screening and Referral Pathway using Shearwave Elastography
- Alberta NAFLD Screening and Referral Pathway using FIB-4 Index
Please visit the following websites for resources on Hepatopulmonary Syndrome:
- Patient section (including educational video): http://hpscare.com/for-patients/
- Healthcare Practitioner section (including online referral form): http://hpscare.com/for-practitioners/
- Researcher section (including description of currently recruiting studies): http://hpscare.com/for-researchers/
English 
French